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The incidence and severity of Clostridium difficile infection (CDI) have dramatically increased in the Western world in recent
years. In contrast, CDI is rarely reported in China, possibly due to under-diagnosis. This article briefly summarizes CDI
incidence, management and preventive strategies. The authors intend to raise awareness of this disease among Chinese
physicians and health workers, in order to minimize the medical and economic burden of a potential epidemic in the
future.
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INTRODUCTION
Clostridium difficile is the most commonly identified cause
of nosocomial diarrhea in the developed world. A steep
increase in the incidence and severity of this disorder has
been observed in western countries for the past several
decades [1], but very limited information is available on
the status of C. difficile infection (CDI) in China. Among
an international sample of physicians from the USA,
Europe and Asia, the level of awareness of this infection
was inadequate [2]. Given the increasing elderly population
and the well-recognized problem of over-prescription of
antibiotics [3], it is important for physicians and healthcare
workers in China to be aware of this global infection.
This review briefly summarizes the disease incidence,
current management, new treatment strategies for CDI,
and its emergence in China.
INCIDENCE AND SEVERITY
C. difficile is an anaerobic, gram-positive, spore-forming
bacterium first isolated in 1935, but not identified until
1978 as the cause of antibiotic-associated pseudomembra-
nous colitis [4]. Despite our growing knowledge of the ep-
idemiology, pathogenesis and treatment of CDI during the
past three decades, the infection has continued to spread
globally from its initial sites in western Europe and North
America to involve eastern Europe, Asia, and Australia.
Furthermore, in North America and Europe, the incidence
and severity of CDI and mortality rates from the disease
have increased dramatically since 2000 [5]. This will proba-
bly also occur in currently low-incidence areas such as China
and Japan.
Very few published reports are available in Asia in
general—and China in particular—on the overall incidence
of C. difficile infection at the national level [6]. A review of
the currently available English and Chinese literature
documented the presence of CDI in mainland China, but
suggested that this infection was only rarely diagnosed
[3]. The CDI rate in the general in-patient population of
China is lower than the reported rates in western countries,
according to the very limited studies conducted so far
(Table 1)[ 7, 8]. However, CDI may be more prevalent
in high-risk patients, such as those in intensive care and
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cited.oncology units [3, 9]. For example, in 44 stem cell transplant
patients, twelve cases (27.3%) of CDI were diagnosed [10].
Of fecal samples from 70 hospitalized patients in Hunan
Province with diarrhea, who had been exposed to antibi-
otics, 30% were positive for C. difficile. Twenty-one isolates
of C. difficile were further assigned to seven ribotypes, with
the dominant types being 017 (48%), 046 (14%) and 012
(14%). However, the epidemic PCR ribotype 027 and 078
strains were not identified [11]. In contrast to the mainland,
an early case of C. difficile belonging to the hypervirulent
strain ribotype 027 was identified in Hong Kong in 2008
[12]. This triggered a survey of C. difficile in a defined
healthcare region in Hong Kong. The investigators
observed a significant increase over five years in the rate
of CDI from 0.53 to 0.95 per 1000 admissions [13], a rate
that is approximately one tenth the rate of CDI observed in
American acute care hospitals [14]. In a 2010 study con-
ducted in a Shanghai hospital, CDI incidence in patients
exposed to antibiotics was 23.8% [15]. As the patients
in these studies were all from one hospital, the reported
high incidence rates may not reflect the rates in China as
a whole.
RISK FACTORS
Use of antibiotics is the most important risk factor for the
development of CDI, due to impairment of colonization
resistance [16]. Ampicillin or amoxicillin, clindamycin,
cephalosporins, and fluoroquinolones are most frequently
associated with CDI [17], but almost all antibiotics have
been associated with CDI. In China, despite increasingly
stringent enforcements of medical guidelines, antibiotic
usage is still loosely regulated in many regions of the
country. Indeed many antibiotics are available without a
prescription in China. Unregulated antibiotic usage may
eventually increase the rate of infection in China.
Another important risk factor for C. difficile infection is
inflammatory bowel disease (IBD), in which C. difficile is the
most common superimposed infection [18–20], and one
that is associated with worse clinical outcomes [18, 21].
IBD, originally considered a ‘western’ disease, has been
reported with increasing frequency and severity in China.
According to a recent report, among 10218 mainland
Chinese patients with ulcerative colitis (UC), 2506 patients
were diagnosed between 1981 and 1990, whereas 7512
were diagnosed between 1991 and 2000 [22]. These figures
represent a threefold increase in the number of UC cases
over the two decades, perhaps related in part to increased
recognition and diagnosis rather than a true increase in
incidence. CDI may be difficult to distinguish from an IBD
flare and thus a high level of suspicion is required. As both
CDI and IBD may be under-recognized in China, it is impor-
tant for physicians to be aware of the clinical features of
these two emerging diseases.
Advanced age also predisposes to risk of acquisition of
CDI as well as severity of infection. The elderly population
continues to grow in Chinese society and, by 2026, more
than 200 million Chinese citizens will be 65 or older [11, 23].
Therefore it is logical to assume that the CDI risk and
severity in China will significantly increase in the future.
TREATMENT OF CDI
Permanent cure of CDI requires restoration of the original
normal colonic microflora, resulting in the elimination of
C. difficile. Current major intervention and emerging treat-
ment strategies are discussed below.
Discontinuation of antibiotics
Discontinuation of antibiotics can often improve patients
with mild clinical symptoms [17]. The standard initial ther-
apy for mild CDI is to discontinue all antibiotics if possible
and monitor the patient’s progress. Almost all patients are
administered an oral antibiotic directed at C. difficile.
Vancomycin, metronidazole and fidaxomicin
Oral administration of vancomycin and metronidazole
are currently the first-line treatments for CDI. For patients
with mild or moderate CDI, metronidazole is adequate.
Oral vancomycin is recommended in patients with severe
CDI, or those who do not respond to or cannot tolerate
metronidazole, or those with multiple recurrences of CDI
Table 1. Reports of CDI incidence in China
City/Region Reported CDI Incidence Reference
Beijing (i) 36 cases among 71428 general patients from 1998–2001 Wang et al. 2004
(ii) 12 cases from 44 patients with stem cell transplants Jia et al. 2008
Shanghai (i) 56 cases among 42936 general patients from 2007–2008 Huang et al. 2008
(ii) 20 cases among 84 patients exposed to antibiotics Gao et al. 2010
Changsha 21 cases from 70 patients with diarrhea and exposed to antibiotics Hawkey et al. 2013
Hong Kong Incidence rate increase from 0.53 (period I: 2004–2008) to 0.95 (period II: 2009) per 1000 admissions Cheng et al. 2011
CDI=Clostridium difficile infection
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therapy for C. difficile infection that is considered severe
as determined by the presence of high fever (>38.38C),
elevation of white blood count >15000 cell/mm
3, albu-
min<2.5g/dL, and age >60 years [25]. All antibiotics, in-
cluding metronidazole and vancomycin impair the fecal
microbiome and its ability to resist colonization, thereby
facilitating recurrent infection [1]. About 25% of patients
treated with metronidazole or vancomycin will suffer a re-
currence after treatment is discontinued; many of these will
have multiple recurrences [26]. In May 2011, the US Food
and Drug Administration approved fidaxomicin for the
treatment of CDI. Compared with vancomycin, fidaxomicin
was associated with a significantly lower rate of recurrence
of CDI (25% vs 15%) [27]. However, its cost-effectiveness
for the treatment of CDI remains questionable [28], as the
drug is considerably more expensive than either metroni-
dazole or vancomycin.
Fecal microbiota transplantation
Fecal microbiota transplantation (FMT) involves the infu-
sion of a fecal suspension from a healthy donor into the
gastro-intestinal tract of a patient with colonic disease [29,
30]. With cure rates of 90–95% reported in uncontrolled
trials, FMT is emerging as the best therapy for recurrent
CDI [30, 31]. In the only randomized, controlled trial, FMT
administrated via a nasojejunal tube resulted in resolution
of C. difficile-associated diarrhea in 81% of patients with
recurrence (vs 27 for controls receiving vancomycin) [32].
Despite the reported high cure rates, FMT has several lim-
itations: to increase safety, screening of all FMT donors is
recommended, including a careful review of their medical
history, and blood and stool tests to detect any possible
stool pathogens [31]. In addition, FMT is esthetically unap-
pealing and logistically challenging. It is likely that the use
of feces may eventually be replaced by a defined bacterial
mixture that confers colonization resistance against C. dif-
ficile. Current research characterizing specific commensal
bacterial species that protect against CDI may lead to
such an attractive future strategy.
Immunotherapy
Immune responses to C. difficile toxins are a key determi-
nant of the outcomes of CDI [33, 34]. Kyne et al. reported
that serum IgG antitoxins directed against toxin A were
protective against CDI in hospitalized patients exposed to
antibiotics [33]. Humanized monoclonal antibodies (MAbs)
against C. difficile toxins have offered a major advance in
passive immunotherapy for CDI. Intravenous infusion
significantly reduced the recurrence of CDI in a large mul-
ticenter, randomized, double-blind, placebo-controlled trial
[35]. The antibodies were administered in conjunction with
vancomycin or metronidazole in patients with acute CDI.
Compared with a 25% recurrence rate in the antibiotics
alone group, only 7% of patients treated with MAbs had
recurrence. Future studies will examine whether these
MAbs will be cost-effective for the treatment of CDI.
Chinese herbal medicines
Chinese herbal mixtures have been used as treatment for
CDI in China [3]. For example, a herbal remedy containing
Puerariaeradix,Scutellariae radix,andRhizomacoptidiswas
beneficial in treating CDI [36]. Combined herbal therapy
using the ‘four miraculous drugs’ plus vancomycin was
more effective when compared with vancomycin alone
[37]. Garlic preparations have also beenreported to improve
pseudomembranous colitis [38]. Although comprehensive
biological studies and randomized controlled clinical trials
are currently lacking, natural products or Chinese herbal
medicines as adjunctive treatment may hold promise as
non-antibiotic-based alternative therapies for CDI.
PREVENTION OF CDI
Antibiotic stewardship
Since nearly all patients with CDI have been previously
exposed to antibiotics, it is important to recognize that
careful restriction of antibiotic usage to conform to clinical
guidelines may help decrease hospital incidence of CDI.
Studies have shown that antibiotic prescription guidelines
reduce C. difficile infection rates by approximately 50% [39,
40]. It has been shown that good antibiotic stewardship
can lead to less overall and inappropriate use of antibiotics,
reductions in CDI, and less emergence of antimicrobial
resistance [41]; therefore, stewardship of antibiotics, espe-
cially broad-spectrum agents, will be an important measure
for CDI prevention in China, where over-prescription is
widely recognized [3].
Environmental decontamination
Use of disposable gloves and gowns, and hand washing
with soaps containing chlorhexidine gluconate have all
been reported to reduce the spread of C. difficile by health-
care workers [42]. Decontamination of rooms and equip-
ment exposed to CDI patients is recommended, using
sporicidal agents [43].
Probiotic strategies in CDI
Probiotics are defined as live micro-organisms that confer a
health benefit to the host. Since CDI is associated with dis-
rupted fecal flora and loss of their normal barrier function,
it is logical to employ probiotic strategies that modulate
gut flora as prophylaxis for this infection. In a recent
meta-analysis including 20 randomized trials and 3818
patients, probiotic prophylaxis reduced the incidence of
CDI by 66% [44]. In a study conducted in Shanghai, the
probiotic combination of Lactobacillus acidophilus CL1285
and Lactobacillus casei LBC80R were given to hospitalized
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and continued for 5 days [15]. This probiotic prophylaxis
resulted in a dose-responsive and significant reduction
of CDI rate (low dose: 9.4%; high dose: 1.2%) compared
with placebo control (23.8%) [15]. In two other trials con-
ducted in England, the probiotic mixture of Lactobacillus
and Bifidobacterium and that of Lactobacillus and
Streptococcus thermophiles both demonstrated efficacy in
lowering CDI incidence without side-effects [45, 46].
However, a recent randomized, controlled trial in the UK
showed no clear benefit of probiotic mixture containing
Lactobacilli and Bifidobacteria in the prevention of CDI in
older inpatients exposed to antibiotics in the hospital [47].
In addition to probiotic bacteria, Saccharomyces boulardii
(Sb), a probiotic yeast, was tested in a double-blind,
randomized, placebo-controlled study in patients with
recurrent CDI [48]. In this study, Sb was used in combination
with metronidazole or vancomycin. A majority (65%) of
the control subjects (antibiotics alone) experienced recur-
rence, compared with only 35% of those receiving antibi-
otics plus Sb. However, a recent clinical trial suggested
that Sb was not effective in preventing CDI in elderly hos-
pitalized patients [49]. Lastly, the use of non-toxigenic
C. difficile to prevent primary or recurrent CDI has been
proposed as an alternative strategy [50], as asymptomatic
colonization of patients with C. difficile (toxigenic or non-
toxigenic strains) is known to be associated with decreased
risk of CDI [51]. Phase II trials using non-toxigenic C. difficile
are currently ongoing. The efficacy of this approach
remains to be seen.
Given their great variety, considering probiotics as a
single entity is likely to over-simplify their diverse mecha-
nisms, functions and clinical benefits. In addition, bacter-
emia or fungemia attributed to probiotic administration
have been reported [52, 53]. Therefore, caution should be
used on immunocompromised patients—or those on immu-
nosuppressive medication—before probiotic usage.
Vaccine development
Vaccination would ultimately provide a cost-effective way
of controlling CDI, as the pathogenesis is entirely attribut-
able to the actions of toxin A and toxin B on the gut
epithelium. Antibodies to the toxins (anti-toxins) interfere
with their binding to cell surface receptors on colonic
epithelial cells [54]. Based on this rationale, the first candi-
date vaccine against C. difficile was a toxoid vaccine
containing formalin-inactivated, purified toxins A and B.
This human vaccine was found to be safe, well-tolerated
and associated with high level responses of serum antitoxin
antibody [55], and was also successful in treating a small
number of patients with recurrent CDI [56]. Phase II clinical
trials of the toxoid vaccine for the prevention of CDI are
currently ongoing. Meanwhile, a recombinant protein-
based vaccine targeting the receptor binding domains
of the C. difficile toxins adjuvanted with S. typhimurium
flagellin induces rapid, high-level protection in a mouse
model of CDI [57], therefore further pre-clinical and clinical
tests are warranted. Another recombinant vaccine candi-
date is co-administration of a cell binding domain fragment
of toxin A and the glucosyl-transferase moiety of toxin B,
which induced protective immunity in hamsters [58]. As
these vaccines are toxin-based, they are unlikely to affect
gut colonization of C. difficile. To functionally target the
colonization step of C. difficile pathogenesis, non-toxins
based vaccine candidates utilizing the bacterial surface pro-
teins or carbohydrates are also being explored [59–62].
CONCLUSIONS
The incidence of CDI in China remains low, partly related to
under-diagnosis; this has resulted in lack of recognition of
CDI as a health problem. China, as the world’s most popu-
lous nation with an increasing elderly population and the
well-recognized problem of antibiotics usage, must be
prepared for a potential C. difficile epidemic. As an accu-
rate estimate of incidence of CDI in China is not known,
large-scale hospital and outpatient screening studies are
needed. Routine diagnostic testing for C. difficile toxins
should be introduced in hospitals and clinics. Better antibi-
otic stewardship, proper hand hygiene by heathcare work-
ers, surveillance and prompt isolation of new cases of CDI
are all recommended measures to prevent CDI. New lines of
antibiotics, non-antibiotic-based approaches including FMT,
immunotherapy and alternative herbal medicine—as well
as vaccine development—hold promise for the treatment
and prevention of CDI.
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